Merger brings together two companies focused on biocatalyst design, synthesis, and use.

Codexis has acquired BioCatalytics, a private company that produces custom and off-the-shelf enzymes. Biocatalysis is a clean technology that uses specialized enzymes to accelerate and improve the economics and environmental impact of chemical reactions. “This acquisition creates a market leader in biocatalysis, bringing the power of clean biobased manufacturing technology to customers seeking alternatives to undesirable or unsustainable chemical processes,” says Alan Shaw, Ph.D., president and CEO.

“BioCatalytics, one of the most respected companies in this growing industry sector, offers a broad catalog of enzyme catalysts and technology services long used by the life science industry in chemical synthesis. Our expanded company will provide a broad product and service platform to serve the pharmaceutical industry worldwide and will also offer exciting new enzyme technologies to our bioindustrial partners.”

Codexis reports that the U.S. enzyme market is expected to increase from $1.6 billion in 2005 to $2.2 billion by 2010, according to industry estimates.

Previous articleMechanism for Gene Silencing in Skin Cancer Discovered
Next articleResearchers Confirm Six New Genetic Variants Related to Heart Disease